Photobiomodulation (low-level light therapy) and dry eye disease.

Clin Exp Optom

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.

Published: July 2021

Dry eye disease is one of the most common, chief-complaints presenting in clinical practice, with a prevalence of up to 50%. Evaporative dry eye, as a result of meibomian gland dysfunction, is thought to be the biggest component factor. Treatments for meibomian gland dysfunction aim to restore tear film homoeostasis and include warm compress therapy, eyelid hygiene, in-office meibomian gland expression and lipid-containing, artificial tears. A recent introduction to the in-office treatments available for meibomian gland dysfunction has been low-level light therapy, also known as photobiomodulation. The technique involves applying red, or near infra-red, radiation using low-power light sources and is suggested to promote tissue repair, decrease inflammation, and relieve pain. This work aims to review the available literature on the efficacy and safety of photobiomodulation in meibomian gland dysfunction and dry eye disease, as well as what is currently known about its mechanism of action.

Download full-text PDF

Source
http://dx.doi.org/10.1080/08164622.2021.1878866DOI Listing

Publication Analysis

Top Keywords

meibomian gland
20
dry eye
16
gland dysfunction
16
eye disease
12
low-level light
8
light therapy
8
treatments meibomian
8
meibomian
5
gland
5
photobiomodulation low-level
4

Similar Publications

Dry eye disease (DED) has become increasingly prevalent in the digital era, largely due to prolonged screen exposure. The excessive use of digital devices contributes to inappropriate blink frequency and dynamics, leading to ocular surface dryness and discomfort. Additionally, digital screen use has broader implications for systemic health, including visual strain, headaches, and disrupted circadian rhythms caused by blue light exposure.

View Article and Find Full Text PDF

Purpose: This study aimed to determine the effect of intense pulsed light (IPL) treatment on meibomian gland disease.

Settings And Design: This is a prospective interventional study.

Methods: Seventy eyes of patients with dry eye disease undergoing three sessions of IPL therapy, 15 days apart, were included.

View Article and Find Full Text PDF

Background: Ocular infections can harm the eye's anatomic structure on numerous levels. They are a global health issue. Endophthalmitis, a serious complication following cataract surgery, can result in substantial ocular morbidity and vision loss despite the administration of antibiotics.

View Article and Find Full Text PDF

Caffeine's protective role in dry eye disease and meibomian gland Dysfunction: Insights from clinical and Experimental models.

Int Immunopharmacol

December 2024

Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address:

Purpose: Inflammation and apoptosis contribute to the development of dry eye disease (DED) and meibomian gland dysfunction (MGD). This study aimed to investigate the effect of caffeine on the ocular surface and tear inflammatory cytokines through clinical, in vivo, and in vitro experiments.

Methods: In the clinical study, comprehensive ophthalmic examinations of participants in the control and the caffeine groups were compared, including ocular surface and tears inflammatory cytokines.

View Article and Find Full Text PDF

Topical Ivermectin-metronidazole gel therapy improves Meibomian gland Function in blepharitis caused by demodex spp.

Cont Lens Anterior Eye

December 2024

Department of Ophthalmology, Molecular Pharmacology and Physiology, FL, United States; Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.

Purpose: To evaluate the efficacy and safety of topical Ivermectin- Metronidazol in the management of demodex infestation and their effect in Meibomian gland dysfunction (MGD) METHODS: Fifty-four patients (108 eyes) with demodex diagnosis and Meibomian gland dysfunction received Ivermectin 0.3 %+Metronidazole 0.5 % gel in the night for 5 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!